4-[(S)-chroman-4-yl]-2-hydroxy-6,6-dimethylmorpholin-3-one | 937399-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 4-[(S)-chroman-4-yl]-2-hydroxy-6,6-dimethylmorpholin-3-one
• 英文别名: 4-[(4S)-3,4-dihydro-2H-chromen-4-yl]-2-hydroxy-6,6-dimethylmorpholin-3-one
• CAS: 937399-36-5
• 化学式: C₁₅H₁₉NO₄
• 分子量: 277.32
• InChiKey: PTRJOBZZOJOFBR-ZSOXZCCMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[(S)-chroman-4-yl]-2-hydroxy-6,6-dimethylmorpholin-3-one 、 3-methoxy-4-(3-methyl-1H-[1,2,4]triazol-1-yl)benzaldehyde 在 三苯基膦氢溴酸盐 、 三乙胺 作用下， 以 乙腈 、 乙醇 为溶剂， 反应 2.0h， 生成 (Z)-4-[(S)-chroman-4-yl]-2-[1-[3-methoxy-4-(3-methyl[1,2,4]triazol-1-yl)phenyl]methylidene]-6,6-dimethylmorpholin-3-one
  参考文献：
  名称：

  EP2019094

  摘要：

  公开号：

文献信息

• Morpholine type cinnamide compound
  申请人：Kimura Teiji

  公开号：US20070117798A1

  公开（公告）日：2007-05-24

  The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R 1 , R 2 , R 3 , and R 4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X 1 represents a C1-6 alkylene group that may be substituted; X a represents a methoxy group or a fluorine atom; X b represents an oxygen atom or a methylene group, provided that X b is only an oxygen atom when X a is a methoxy group; and Ar 1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.

  本发明涉及一种由式(I)表示的化合物或其药理学上可接受的盐，其中R1、R2、R3和R4相同或不同，并且每个代表氢原子或C1-6烷基基团；X1代表可能被取代的C1-6烷基基团；Xa代表甲氧基团或氟原子；Xb代表氧原子或亚甲基基团，前提是当Xa为甲氧基团时，Xb仅为氧原子；Ar1代表可能具有卤素原子等取代基的芳基、吡啶基、芳氧基或吡啶氧基；以及将该化合物或盐用作药物剂的用途。
• HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE
  申请人：Kimura Teiji

  公开号：US20090203697A1

  公开（公告）日：2009-08-13

  Disclosed is a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof. Also disclosed is a use of the compound or salt as a pharmaceutical product. (In the formula, Ar 1 represents a triazolyl group or the like which may be substituted with a C 1-6 alkyl group or the like; Ar 2 represents a phenyl group or the like which may be substituted with a C 1-6 alkoxy group or the like; X 1 represents —CR 3 ═CR 4 — (wherein R 3 and R 4 respectively represent a C 1-6 alkyl group or the like); and R 1 and R 2 respectively represent a C 1-6 alkyl group or the like.)

  本发明公开了下式(I)所表示的化合物或其药学上可接受的盐。同时，本发明还公开了该化合物或盐作为药物产品的用途。（其中，Ar1代表三唑基或类似物，可以用C1-6烷基或类似物取代；Ar2代表苯基或类似物，可以用C1-6烷氧基或类似物取代；X1代表—CR3═CR4—（其中，R3和R4分别代表C1-6烷基或类似物）；而R1和R2分别代表C1-6烷基或类似物。）
• MORPHOLINE TYPE CINNAMIDE COMPOUND
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1953154A1

  公开（公告）日：2008-08-06

  The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R1, R2, R3, and R4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X1 represents a C1-6 alkylene group that may be substituted; Xa represents a methoxy group or a fluorine atom; Xb represents an oxygen atom or a methylene group, provided that Xb is only an oxygen atom when Xa is a methoxy group; and Ar1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.

  本发明涉及一种由式 (I) 代表的化合物： 或其药理上可接受的盐，其中 R1、R2、R3 和 R4 相同或不同，且各自代表氢原子或 C1-6 烷基；X1 代表可被取代的 C1-6 亚烷基；Xa 代表甲氧基或氟原子；Xb代表氧原子或亚甲基，但当Xa为甲氧基时，Xb仅为氧原子；Ar1代表芳基、吡啶基、芳氧基或吡啶氧基，可具有卤素原子等取代基；以及将化合物或盐用作药剂。
• US7618960B2
  申请人：——

  公开号：US7618960B2

  公开（公告）日：2009-11-17